Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study

DiscussionMelatonin has been found to positively impact our immune system, inhibit angiogenesis, stimulate apoptosis in malignant cells, and act as a potent antioxidant. Previous clinical trials have used similar doses of melatonin with positive results, particularly in advanced stages of cancer. Previous animal and human studies have found the toxicity of the hormone to be low. Considering the potential benefits and limited risks of melatonin, as well as its global availability, it may be a suitable candidate for an adjuvant treatment in patients with uveal melanoma.Trial registrationOur trial protocol has been approved and registered by the Swedish Medical Products Agency on June 22, 2022 (EudraCT 2022 –500,307-49–00). Our trial registration number is NCT05502900, and the date of registration is August 16, 2022.
Source: Trials - Category: Research Source Type: clinical trials